Non-therapeutic Clinical Trial for All Brain Tumors

PILOT STUDY TO ASSESS THE EFFECT OF VARDENAFIL ON BLOOD BRAIN AND BLOOD TUMOR PERMEABIITY (IRB 22499)


Pilot study to assess the effect of Vardenafil on blood-brain and blood-tumor permeability using dynamic contrast enhanced magnetic resonance Imaging

  • Malignant primary or metastatic brain tumors with at least 1.0 cm x 1.0 cm of measureable disease
  • Eligible tumor types include but are not limited to histologically proved WHO grade II, grade III, or grade IV gliomas of any histological subtype (eg, grade II astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastroctyoma, glioblastoma, gliosarcoma), CNS lymphoma, medulloblastoma, or a brain lesion with radiographic appearance consistent with metastasis in a patient with a primary neoplasm known to metastatize to the brain
  • Vardenafil is well-tolerated drug approved by the FDA for erectile dysfunction.

The primary objective of this study is to quantitatively assess the effect of vardenafil on the blood-brain and blood-tumor barrier using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Additionally, this study aims to evaluate the DCE-MRI protocol for the purpose of detecting drug effect on blood-brain and blood-tumor barrier permeability.

Surasak Phuphanich, MD, FAAN
Director, Neuro-oncology Program
phuphanich@cshs.orG
Phone: (310) 423-8100

Christy Davis, RN
christy.davis2@cshs.org
Phone: (310) 423-0022

print button
WP2